Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 EPS of ($1.85), $1.55 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $99.41 million versus the consensus estimate of $95.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.